Operating costs and other operating income (Tables)
|
12 Months Ended |
Dec. 31, 2025 |
|---|
| Operating costs and other operating income |
|
| Summary of research and development expenditure |
| | | | | | | | | | | | Year ended December 31, | | | 2025 | | 2024 | | 2023 | | | | | (Euro, in thousands) | Personnel costs | | € | (147,197) | | € | (87,740) | | € | (95,788) | Subcontracting | | | (232,906) | | | (160,076) | | | (82,997) | Disposables and lab fees and premises costs | | | (10,812) | | | (17,629) | | | (18,083) | Amortization, depreciation and impairment | | | (42,371) | | | (35,378) | | | (22,254) | Professional fees | | | (7,611) | | | (15,949) | | | (9,272) | Other operating expenses | | | (18,524) | | | (18,687) | | | (12,900) | Total R&D expenses | | € | (459,421) | | € | (335,459) | | € | (241,294) |
|
| Summary of R&D expenditure by program |
| | | | | | | | | | | | Year ended December 31, | | | 2025 | | 2024 | | 2023 | | | | | (Euro, in thousands) | | | | | | | | | | | SIKi program | | € | (12,772) | | € | (18,400) | | € | (18,900) | TYK2 program on GLPG3667 | | | (36,744) | | | (34,965) | | | (31,289) | Cell therapy programs in oncology | | | (295,610) | | | (170,998) | | | (82,218) | Other discovery programs | | | (114,295) | | | (111,096) | | | (108,887) | Total R&D expenses | | € | (459,421) | | € | (335,459) | | € | (241,294) |
|
| Summary of sales and marketing expenses |
| | | | | | | | | | | | Year ended December 31, | | | 2025 | | 2024 | | 2023 | | | | | (Euro, in thousands) | Personnel costs | | € | (6,601) | | € | (6,561) | | € | (2,997) | Amortization, depreciation and impairment | | | 3,465 | | | (4,475) | | | (113) | External outsourcing costs | | | (1,392) | | | (2,813) | | | (1,776) | Professional fees | | | (62) | | | (904) | | | (131) | Other operating expenses | | | (1,510) | | | (2,440) | | | (659) | Total sales and marketing expenses | | € | (6,100) | | € | (17,193) | | € | (5,676) |
|
| Summary of general and administrative expenses |
| | | | | | | | | | | | Year ended December 31, | | | 2025 | | 2024 | | 2023 | | | | | (Euro, in thousands) | Personnel costs | | € | (74,390) | | € | (52,642) | | € | (66,098) | Amortization, depreciation and impairment | | | (12,951) | | | (8,697) | | | (15,978) | Legal and professional fees | | | (29,515) | | | (33,960) | | | (23,250) | Other operating expenses | | | (30,477) | | | (21,946) | | | (22,963) | Total general and administrative expenses | | € | (147,333) | | € | (117,245) | | € | (128,289) |
|
| Schedule of other income |
| | | | | | | | | | | | Year ended December 31, | | | 2025 | | 2024 | | 2023 | | | | | (Euro, in thousands) | Grant income | | € | 57 | | € | 2,035 | | € | 6,618 | R&D incentives income | | | 27,218 | | | 27,223 | | | 32,968 | Fair value adjustment contingent consideration payable | | | 21,760 | | | — | | | — | Other | | | 4,458 | | | 11,515 | | | 7,686 | Total other operating income | | € | 53,493 | | € | 40,773 | | € | 47,272 |
|
| Schedule of R&D incentives income |
| | | | | | | | | | | | Year ended December 31, | | | 2025 | | 2024 | | 2023 | | | | | (Euro, in thousands) | Income from innovation incentive system in France | | € | — | | € | 2,056 | | € | 5,881 | Income from Belgian R&D incentives | | | 13,610 | | | 16,943 | | | 16,535 | Tax rebates on payroll withholding taxes of R&D personnel (Belgium & the Netherlands) | | | 13,608 | | | 8,224 | | | 10,552 | Total R&D incentives income | | € | 27,218 | | € | 27,223 | | € | 32,968 |
|